Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139


Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Supekar NT, Lakshminarayanan V, Capicciotti CJ, Sirohiwal A, Madsen CS, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ.

Chembiochem. 2018 Jan 18;19(2):121-125. doi: 10.1002/cbic.201700424. Epub 2017 Nov 30.


Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet.

Myers CE, Hoelzinger DB, Truong TN, Chew LA, Myles A, Chaudhuri L, Egan JB, Liu J, Gendler SJ, Cohen PA.

Oncotarget. 2017 Jan 17;8(3):5426-5438. doi: 10.18632/oncotarget.14576.


Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA.

Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.


A Flow Cytometry-Based Assay for Procoagulant Platelet Polyphosphate.

Labberton L, Long AT, Gendler SJ, Snozek CL, Stavrou EX, Nickel KF, Maas C, Blankenberg S, Hernandez JS, Renné T.

Cytometry B Clin Cytom. 2018 Mar;94(2):369-373. doi: 10.1002/cyto.b.21492. Epub 2016 Nov 28.


Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Pathangey LB, Lakshminarayanan V, Suman VJ, Pockaj BA, Mukherjee P, Gendler SJ.

Biomolecules. 2016 Jun 29;6(3). pii: E31. doi: 10.3390/biom6030031.


Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Manrique SZ, Dominguez AL, Mirza N, Spencer CD, Bradley JM, Finke JH, Lee JJ, Pease LR, Gendler SJ, Cohen PA.

Oncotarget. 2016 Jul 12;7(28):42919-42942. doi: 10.18632/oncotarget.10190.


MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ.

PLoS One. 2016 Jan 20;11(1):e0145920. doi: 10.1371/journal.pone.0145920. eCollection 2016.


Muc1 enhances the β-catenin protective pathway during ischemia-reperfusion injury.

Al-Bataineh MM, Kinlough CL, Poland PA, Pastor-Soler NM, Sutton TA, Mang HE, Bastacky SI, Gendler SJ, Madsen CS, Singh S, Monga SP, Hughey RP.

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F569-79. doi: 10.1152/ajprenal.00520.2015. Epub 2016 Jan 6.


Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ.

Chem Commun (Camb). 2015 Jun 25;51(50):10214-7. doi: 10.1039/c5cc02199e. Epub 2015 May 29.


Muc1 is protective during kidney ischemia-reperfusion injury.

Pastor-Soler NM, Sutton TA, Mang HE, Kinlough CL, Gendler SJ, Madsen CS, Bastacky SI, Ho J, Al-Bataineh MM, Hallows KR, Singh S, Monga SP, Kobayashi H, Haase VH, Hughey RP.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1452-62. doi: 10.1152/ajprenal.00066.2015. Epub 2015 Apr 29.


Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ.

Cancer Res. 2014 Dec 1;74(23):6845-55. doi: 10.1158/0008-5472.CAN-14-0836. Epub 2014 Oct 8.


Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Abdel-Aal AB, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ.

Chembiochem. 2014 Jul 7;15(10):1508-13. doi: 10.1002/cbic.201402077. Epub 2014 May 30.


Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells.

Poh TW, Madsen CS, Gorman JE, Marler RJ, Leighton JA, Cohen PA, Gendler SJ.

Clin Cancer Res. 2013 Sep 15;19(18):5039-52. doi: 10.1158/1078-0432.CCR-13-0278. Epub 2013 Jul 19.


Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA.

Cancer J. 2013 Jul-Aug;19(4):353-64. doi: 10.1097/PPO.0b013e31829da0ae. Review.


Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.


Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z.

Int J Cancer. 2013 Apr 15;132(8):1860-7. doi: 10.1002/ijc.27872. Epub 2012 Oct 25.


Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P.

Cancer Immunol Immunother. 2012 Nov;61(11):2055-65. doi: 10.1007/s00262-012-1264-y. Epub 2012 Apr 28.


MUC1 regulates PDGFA expression during pancreatic cancer progression.

Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, Kidiyoor A, Dalia R, Gendler SJ, Mukherjee P.

Oncogene. 2012 Nov 22;31(47):4935-45. doi: 10.1038/onc.2011.651. Epub 2012 Jan 23.


Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6. doi: 10.1073/pnas.1115166109. Epub 2011 Dec 14.


Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal.

Kinlough CL, Poland PA, Gendler SJ, Mattila PE, Mo D, Weisz OA, Hughey RP.

J Biol Chem. 2011 Nov 11;286(45):39072-81. doi: 10.1074/jbc.M111.289504. Epub 2011 Sep 20.


Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.

Pinkhasov J, Alvarez ML, Rigano MM, Piensook K, Larios D, Pabst M, Grass J, Mukherjee P, Gendler SJ, Walmsley AM, Mason HS.

Plant Biotechnol J. 2011 Dec;9(9):991-1001. doi: 10.1111/j.1467-7652.2011.00614.x. Epub 2011 Jul 11.


Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.

Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, Hwang SI, Lee YY, Gendler SJ, Mukherjee P.

Cancer Res. 2011 Jul 1;71(13):4432-42. doi: 10.1158/0008-5472.CAN-10-4439. Epub 2011 May 10.


Importance and regulation of the colonic mucus barrier in a mouse model of colitis.

Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L, Phillipson M.

Am J Physiol Gastrointest Liver Physiol. 2011 Feb;300(2):G327-33. doi: 10.1152/ajpgi.00422.2010. Epub 2010 Nov 25.


MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.

Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, Gendler SJ, Mukherjee P.

Oncogene. 2011 Mar 24;30(12):1449-59. doi: 10.1038/onc.2010.526. Epub 2010 Nov 22.


Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model.

Pinkhasov J, Alvarez ML, Pathangey LB, Tinder TL, Mason HS, Walmsley AM, Gendler SJ, Mukherjee P.

Cancer Immunol Immunother. 2010 Dec;59(12):1801-11. doi: 10.1007/s00262-010-0906-1. Epub 2010 Sep 8.


Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.

Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J.

Oncogene. 2009 Dec 3;28(48):4225-36. doi: 10.1038/onc.2009.268. Epub 2009 Sep 7.


Expression of human MUC1 during early pregnancy in the human MUC1 transgenic mouse model.

Dharmaraj N, Gendler SJ, Carson DD.

Biol Reprod. 2009 Dec;81(6):1182-8. doi: 10.1095/biolreprod.109.079418. Epub 2009 Aug 14.


Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow.

Poh TW, Bradley JM, Mukherjee P, Gendler SJ.

Cancer Res. 2009 Apr 15;69(8):3554-62. doi: 10.1158/0008-5472.CAN-08-3806. Epub 2009 Apr 7.


The gastric mucus layers: constituents and regulation of accumulation.

Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler SJ, Sandler S, Persson AE, Hansson GC, Holm L.

Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G806-12. doi: 10.1152/ajpgi.90252.2008. Epub 2008 Aug 21.


Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA.

J Biol Chem. 2008 Oct 3;283(40):26985-95. doi: 10.1074/jbc.M805036200. Epub 2008 Jul 14.


The MUC1 Cytoplasmic Tail and Tandem Repeat Domains Contribute to Mammary Oncogenesis in FVB Mice.

Hattrup CL, Bradley JM, Kotlarczyk KL, Madsen CS, Hentz JG, Marler RJ, Gendler SJ.

Breast Cancer (Auckl). 2008;1:57-63. Epub 2008 Apr 17.


MUC1 mucin is a negative regulator of toll-like receptor signaling.

Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, Kim KC.

Am J Respir Cell Mol Biol. 2008 Mar;38(3):263-8. Epub 2007 Dec 13.


Structure and function of the cell surface (tethered) mucins.

Hattrup CL, Gendler SJ.

Annu Rev Physiol. 2008;70:431-57. Review.


Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Akporiaye ET, Bradley-Dunlop D, Gendler SJ, Mukherjee P, Madsen CS, Hahn T, Besselsen DG, Dial SM, Cui H, Trevor K.

Vaccine. 2007 Sep 28;25(39-40):6965-74. Epub 2007 Jul 24.


MUC1 cell surface mucin is a critical element of the mucosal barrier to infection.

McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, Florin TH, Hill GR, Korolik V, McGuckin MA.

J Clin Invest. 2007 Aug;117(8):2313-24.


Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells.

Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, Gendler SJ, Hollingsworth MA.

Cancer Res. 2007 Jun 1;67(11):5201-10.


MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ.

Vaccine. 2007 Feb 19;25(9):1607-18. Epub 2006 Nov 16.


Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways.

Thompson EJ, Shanmugam K, Hattrup CL, Kotlarczyk KL, Gutierrez A, Bradley JM, Mukherjee P, Gendler SJ.

Mol Cancer Res. 2006 Jul;4(7):489-97.


MUC1 alters oncogenic events and transcription in human breast cancer cells.

Hattrup CL, Gendler SJ.

Breast Cancer Res. 2006;8(4):R37.


Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice.

Wang HH, Afdhal NH, Gendler SJ, Wang DQ.

Gastroenterology. 2006 Jul;131(1):210-22.


Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.

Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.

Hum Gene Ther. 2006 Jun;17(6):661-8.


MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.

Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A.

Histol Histopathol. 2006 Aug;21(8):849-55. doi: 10.14670/HH-21.849.


Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice.

Lu W, Hisatsune A, Koga T, Kato K, Kuwahara I, Lillehoj EP, Chen W, Cross AS, Gendler SJ, Gewirtz AT, Kim KC.

J Immunol. 2006 Apr 1;176(7):3890-4.


Increased levels of mucins in the cystic fibrosis mouse small intestine, and modulator effects of the Muc1 mucin expression.

Malmberg EK, Noaksson KA, Phillipson M, Johansson ME, Hinojosa-Kurtzberg M, Holm L, Gendler SJ, Hansson GC.

Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G203-10. Epub 2006 Feb 23.


Regulation of mucin genes in chronic inflammatory airway diseases.

Voynow JA, Gendler SJ, Rose MC.

Am J Respir Cell Mol Biol. 2006 Jun;34(6):661-5. Epub 2006 Feb 2. Review.


Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression.

Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, Kuskowski MA, Stelow EB, Mukherjee P, Gendler SJ, Wong GY, Mantyh PW.

Pain. 2005 Dec 15;119(1-3):233-46. Epub 2005 Nov 18.


Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.

Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.

Gene Ther. 2006 Jan;13(1):60-6.


Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.

Xu Y, Sette A, Sidney J, Gendler SJ, Franco A.

Immunol Cell Biol. 2005 Aug;83(4):440-8.


Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P.

Breast Cancer Res. 2005;7(4):R422-35. Epub 2005 Apr 4.

Supplemental Content

Loading ...
Support Center